Skip to main content
Premium Trial:

Request an Annual Quote

Trovagene Reports $5.4 Million Loss in Q3

NEW YORK (GenomeWeb) – Trovagene announced Thursday after the close of the market that its third quarter net loss widened as its revenues inched up to $57,000 from $44,000 in Q3 2014.

The firm posted a net loss of $5.4 million, or $.28 per share, for the three months ended Sept. 30, as compared to a net loss of $4.4 million, or $.25 per share, in Q3 2014.

The increased loss is primarily due to an increase in operating expenses as compared to a year ago, the firm said in a statement.

Its R&D spending rose 117 percent to $2.0 million, up from $916,000, and its SG&A spending fell 9 percent to $2 million from $2.2 million.

San Diego-based Trovagene is developing a cell-free molecular diagnostic platform for the detection and monitoring of DNA in urine, offering physicians a non-invasive method to determine mutations and monitor response to cancer.

Trovagene CEO Antonius Schuh said that the firm's cell-free cancer diagnostic assay is gaining recognition within the medical community. "Recently published data in the journal Cancer Discovery demonstrates that urinary cell-free DNA can outperform tissue biopsy for the detection of the BRAF V600E mutation," Schuh said.

The firm also recently expanded its relationship with Memorial Sloan-Kettering to include a new clinical study evaluating its precision cancer monitoring platform in lung cancer.

Trovagene finished the quarter with cash and cash equivalents of $31.2 million.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.